Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 384

Sort by

Sort Order Select

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Blood blood.2024026186.

https://doi.org/10.1182/blood.2024026186

Published: 2024

Includes: Supplemental data

Journal Articles

How I treat refractory and relapsed acute myeloid leukemia

Felicitas Thol, Hartmut Döhner, Arnold Ganser

Blood (2024) 143 (1): 11–20.

https://doi.org/10.1182/blood.2023022481

Published: 2024

Journal Articles

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Michael Lübbert, Claudia Schmoor, Olga Grishina, Christoph Rummelt, Johanna Thomas, Michael Heuser, Konstanze Döhner, Hartmut Döhner, Heiko Becker, Ralph Wäsch

Blood (2023) 142 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2023-181871

Published: 2023

Journal Articles

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Blood (2023) 142 (Supplement 1): 63.

https://doi.org/10.1182/blood-2023-185627

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Treosulfan-Based Reduced-Toxicity Conditioning for Elderly Patients with High-Risk Myelodysplastic and Myeloproliferative Disease for Allogeneic Hematopoietic Stem Cell Transplantation

Adela Maria Neagoie, Verena Wais, Andrea Gantner, Jacqueline Schnell, Katrin Strauss, Conrad Weidt, Hartmut Dohner, Donald Werner Bunjes, Elisa Sala

Blood (2023) 142 (Supplement 1): 6956.

https://doi.org/10.1182/blood-2023-188767

Published: 2023

Journal Articles

Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1 -Mutated Myeloid Malignancies

Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, Ivory Tang, Yanis Tazi, Amanda Gilkes, Ian Thomas, Lars Bullinger, Konstanze Döhner, Hartmut Dohner, Brian Huntly, Nigel H. Russell, Sanam Loghavi, Elli Papaemmanuil

Blood (2023) 142 (Supplement 1): 818.

https://doi.org/10.1182/blood-2023-179598

Published: 2023

Journal Articles

The Genomic Landscape and Its Clinical Implication in NPM1 -Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial

Blood (2023) 142 (Supplement 1): 4311.

https://doi.org/10.1182/blood-2023-185566

Published: 2023

Journal Articles

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Luca Guarnera, Soren Lehmann, Konstanze Döhner, Hartmut Döhner, Uwe Platzbecker, Nigel H. Russell, Richard Dillon, Ian Thomas, Gert Ossenkoppele, Marco Vignetti, Edoardo la Sala, Alfonso Piciocchi, Angela Villaverde Ramiro, Laura Tur, Carmelo Gurnari, Lars Bullinger, Jesús María Hernández-Rivas, Maria Teresa Voso

Blood (2023) 142 (Supplement 1): 727.

https://doi.org/10.1182/blood-2023-185121

Published: 2023

Journal Articles

Molecular Measurable Residual Disease in Patients with Newly Diagnosed m IDH1 Acute Myeloid Leukemia Treated with Ivosidenib + Azacitidine

Courtney D. DiNardo, Dylan Marchione, Michael Heuser, Jianan Hui, Diego Gianolio, Scott Daigle, Sung Choe, Prapti Patel, Stephane De Botton, Hartmut Dohner

Blood (2023) 142 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2023-180549

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

Prognostic Impact of Clonality of Myelodysplasia-Related Gene Mutations in AML

Rabea Mecklenbrauck, Nora Borchert, Piroska Klement, Carolin Funke, Maximilian Brandes, Louisa-Kristin Dallmann, Walter Fiedler, Jürgen Krauter, Arne Trummer, Bernd Hertenstein, Verena I. Gaidzik, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Felicitas Thol, Michael Heuser

Blood (2023) 142 (Supplement 1): 817.

https://doi.org/10.1182/blood-2023-179412

Published: 2023

Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2023-187651

Published: 2023

Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Blood (2023) 142 (11): 961–972.

https://doi.org/10.1182/blood.2023020013

Published: 2023

Includes: Supplemental data

Journal Articles

The International Consensus Classification of acute leukemias of ambiguous lineage

Olga K. Weinberg, Daniel A. Arber, Hartmut Döhner, Charles G. Mullighan, Etan Orgel, Anna Porwit, Richard M. Stone, Michael J. Borowitz

Blood (2023) 141 (18): 2275–2277.

https://doi.org/10.1182/blood.2022019493

Published: 2023

Journal Articles

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Blood (2023) 141 (2): 156–167.

https://doi.org/10.1182/blood.2021014901

Published: 2023

Includes: Supplemental data

Journal Articles

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Blood (2022) 140 (21): 2228–2247.

https://doi.org/10.1182/blood.2022015853

Published: 2022

Includes: Supplemental data

Journal Articles

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2010–2013.

https://doi.org/10.1182/blood-2022-166084

Published: 2022

NARROW

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

How I treat refractory and relapsed acute myeloid leukemia

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Treosulfan-Based Reduced-Toxicity Conditioning for Elderly Patients with High-Risk Myelodysplastic and Myeloproliferative Disease for Allogeneic Hematopoietic Stem Cell Transplantation

Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1 -Mutated Myeloid Malignancies

The Genomic Landscape and Its Clinical Implication in NPM1 -Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Molecular Measurable Residual Disease in Patients with Newly Diagnosed m IDH1 Acute Myeloid Leukemia Treated with Ivosidenib + Azacitidine

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Prognostic Impact of Clonality of Myelodysplasia-Related Gene Mutations in AML

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

The International Consensus Classification of acute leukemias of ambiguous lineage

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only